India Accelerates Efforts to Combat Chandipura Virus with New Treatments in Development
Indian scientists are developing a vaccine and antivirals for the Chandipura virus, which causes encephalitis in children. The ICMR-NIV Pune is working on advancements, with Fevipiravir showing promise in inhibiting the virus. Human trials are slated to begin soon, aiming to curb disease outbreaks across several states.
- Country:
- India
Indian scientists, leading an urgent initiative, are developing a vaccine and antivirals to combat the Chandipura virus, known for causing encephalitis, Dr. Naveen Kumar, director at ICMR-NIV Pune, reported. Currently, these treatments are not yet available commercially, but significant progress is being made.
Dr. Kumar highlighted Fevipiravir as a promising drug, demonstrating its efficacy in inhibiting the virus's growth in cell and animal models. Looking ahead, human trials for this potential treatment are expected to commence shortly, marking a critical step forward in mitigating the disease's impact.
The Chandipura virus, identified in 1965, predominantly affects children aged between 5 and 15, with fatal cases occurring within 24-48 hours post-infection. Transmitted by sandflies, symptoms include fever, vomiting, and loss of consciousness. States at high risk include Maharashtra, Gujarat, and others. Efforts by ICMR and multi-sectoral partnerships remain vital to controlling outbreaks.
(With inputs from agencies.)
Google News